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 Thyroid cancer (TC) is the most common neoplasm of the endocrine system. In 2011, the standardized incidence 
rate in Poland was 7.4 for women and 1.7 for men [1]. This rate is characterized by a steady increase. However, it 
is not accompanied by an increase in mortality [2, 3]. On the contrary, a significant reduction is observed due to 
diagnosing cancer at earlier stages and improved treatment effectiveness [4]. 
Over 90% of all TC are differentiated thyroid cancers (DTC), which are characterized by favorable prognosis, i.e. 
10-year survival in 90-95% of cases [5]. As a result of treatment, more than 80% of patients recover, although in 
15% of cases local recurrence is observed, with distant metastases being diagnosed in 5-10% of cases. Relapse 
frequently occurs within the first five years, but there have been reports of recurrences or distant metastases even 
40 years later; therefore, lifetime oncological follow-up is required [6]. 
Taking into account the very good prognosis and the need for long-term monitoring, patients should be offered the 
safest and most comfortable procedures. 
The biggest burden for patients with DTC resulting from oncological treatment and follow up is the use of a 
radioiodine (
131
I) and periods of hypothyroidism required to evaluate TSH-stimulated thyroglobulin (Tg) - a 
sensitive and specific marker for DTC. 
The use of 
131
I is associated with a dose-dependent increase in the risk of secondary neoplasms: leukemia, bone 
cancer, stomach and colorectal cancer, salivary gland cancer and soft tissue tumors. Compared to the general 
population, in patients treated with 
131
I an overall 27% increase in the risk of other tumors was observed. The 
adverse effects of 
131
I are also manifested as impaired function of salivary glands, and parotid glands in particular 
[7, 8]. 
Periods of hypothyroidism lasting for approximately 4-6 weeks are associated with disturbances in the patients' 
symptoms of hypothyroidism, deteriorating patients' physical, intellectual and social functioning. Additional 
treatment is often needed due to exacerbation of comorbid conditions and inability to work [9]. 
The introduction of recombinant human TSH (rhTSH) was a breakthrough in the care of patients with DTC. 
Recombinant human TSH (rhTSH) is a protein produced by the ovarian cell lines of Chinese hamsters transfected 
with DNA that encodes both subunits of the protein. The bioactivity of recombinant TSH depends on the degree of 
saturation of the carbohydrate component with the sialic acid residues, and is as high as for endoTSH in overt 
hypothyroidism and significantly higher than for endoTSH in the state of hormonal balance. Recombinant TSH 
strongly stimulates iodine uptake as well as Tg and thyroid hormone synthesis in both thyrocytes and DTC cells. 
The results of studies evaluating the impact of rhTSH on 
131
I pharmacokinetics are of great importance, indicating 
a decrease in isotope radiotoxicity (reduction of exposure dose for the bone marrow by a third) by accelerating the 
renal clearance of iodine and reduction of the effective half-life of 
131
I in the whole body from 0.54 +/- 0.1 day to 
0.43 +/- 0.1 day. At the same time, the effective half-life of 
131
I is extended in the thyroid gland residues, which is a 
beneficial effect that determines effectiveness of the treatment [10–12]. 
Registered indications relate to the use of rhTSH for ablation in patients after total thyroidectomy with no evidence 
of distant metastases, as well as in monitoring the course of the disease. Numerous studies [13, 14] confirm the 
equal effectiveness of ablation for 
131
I at 1100 MBq and 3700 MBq regardless of the method of stimulation: rhTSH 
or thyroid hormone withdrawal (HiLo -T1-T3, N0, N1, Mo; ESTIMABL -T1-T2, No, N1, M0). 
The results of multicenter studies in patients with T4 carried out by Bartenstein et al. and published in 2013 also 
confirmed the high efficacy of ablation using rhTSH in the higher risk group [15]. 
The results of a ten-year follow-up study in patients undergoing ablation using rhTSH, presented by Malinoro et 
al., demonstrated equal frequency of recurrence episodes, distant metastases and persistent disease compared with 
patients treated with thyroid hormone withdrawal [16]. 
Recombinant human TSH has not been registered for the treatment of patients with metastatic diseases; however, 
such attempts are being made. The first reports of a successful treatment with 
131
I after rhTSH stimulation in 
patients with distant metastases were published in 2000 by Luster [17] et colleagues, and in 2003 by Jarząb et al. 
[18]. Studies conducted by Tal et al. demonstrated equal 5-year survival rates in patients with DTC metastases to 
the lungs and bones, regardless of the method of preparation for the 
131
I therapy: rhTSH or thyroid hormone 
withdrawal [19]. 
An important indication for the use of rhTSH is disease monitoring. The first assessment concerning the 
effectiveness of ablation therapy is carried out 6-12 months after radioiodine treatment. The assessment includes 
rhTSH-stimulated Tg levels, anti-Tg antibodies levels, thyroid ultrasound and whole-body scintigraphy. In more 
than 80% of patients, serum Tg levels reach the highest values at day 5 after administration of rhTSH. Evaluation 
of serum Tg levels after TSH stimulation is the most effective method of disease monitoring. The sensitivity of Tg 
measurement during the treatment with L-T4 is definitely lower: in 20% of patients with metastases to the lymph 
nodes and in 5% with distant metastases it may be false negative [20]. 
Periodic monitoring of patients with complete remission of the disease must be carried out over a period of many 
years. In patients with a low risk of relapse, in the absence of anti-Tg, it is possible to omit the whole-body 
scintigraphy and only to evaluate the stimulated Tg and perform the ultrasound examination of the neck and chest 
X-ray [20]. 
The use of rhTSH in preparing patients for the treatment of metastatic disease is justified if the patient's condition 
does not allow a break in LT4 administration in fear of exacerbation of the symptoms of neoplasm or 
comorbidities, and if it is impossible to achieve endogenous stimulation due to hypopituitarism or hormonally 
active metastases. 
New opportunities for the implementation of rhTSH include: improvement of the efficiency of imaging patients 
using FDG PET/CT after rhTSH administration, diagnosis of congenital hypothyroidism, treatment of nodular 
goiter with 
131
I, assessment of thyroid reserve in elderly patients, testing of TSH-dependent immune system genes, 
evaluation of differences in the metabolism of adipose tissue and secretion of adipokines [21]. 
Summary 
• Diagnosis and treatment with 131I is equally effective regardless of the method of TSH stimulation: with 
rhTSH or with LT4 withdrawal. 
• Recombinant human TSH extends the effective half-life of radioiodine in the thyroid residues, which may 
increase the effectiveness of the treatment. 
• Minimized radiotoxicity of 131I may reduce the risk of secondary malignancies. 
• Assistance is required in avoiding hypothyroidism and related symptoms, deterioration of quality of life 
and inability to work professionally. 
• Despite the high price of rhTSH, the total economic analysis of the cost/benefit ratio suggests that its use is 
favorable. 
References 
1.  Didkowska J, Wojciechowska U, Zatoński W: Cancer in Poland in 2011. Warsaw; 2013. ISSN 0867-8251 
2.  Davies L, Welch HG: Increasing Incidence of Thyroid Cancer in the United States,1973–2002. JAMA 
2006,295(18):2164–2167. 10.1001/jama.295.18.2164 
3.  Hall SF, Walker H, Siemens R, Schneeberg A: Increasing detection and increasing incidence in thyroid 
cancer. World J Surg 2009,33(12):2567–2571. 10.1007/s00268-009-0226-9 
4.  Davies L, Ouellette M, Huntr M, Welch HG: The increasing incidence of small thyroid cancers: where are 
the cases coming from? Laryngoscope 2010,120(12):2446–2451. 10.1002/lary.21076 
5.  Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HG: Clinical review 170: a 
systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for 
well-differentiated thyroid cancer. J Clin Endocrinol Metab 2004,89(8):3668–3676. 10.1210/jc.2003-031167 
6.  Mazzaferri EL, Jhiang SM: Long-term impact of initial surgical and medical therapy on papillary and 
follicular thyroid cancer. AM J Med 1994,97(5):418–428. 10.1016/0002-9343(94)90321-2 
7.  de Vathaire F: The carcinogenic effects of radioiodine therapy for thyroid carcinoma. Nat Clin Pract 
Endocrinol Metab 2008,4(4):180–181. 10.1038/ncpendmet0761 
8.  Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD: The risk of second primary malignancies 
up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 
2008,93(2):504–515. 10.1210/jc.2007-1154 
9.  Luster M, Felbinger R, Dietlein M, Reiners C: Thyroid hormone withdrawal in patients with differentiated 
thyroid carcinoma: A one hundred thirty-patient pilot survey on consequences of hypothyroidism and a 
pharmacoeconomic comparison to recombinant thyrotropin administration. Thyroid 2005,15(10):1147–1155. 
10.1089/thy.2005.15.1147 
10.  Taieb D, Sebag F, Forman-Ara B, Portal T, Baumstarck-Barrau K, Fortanier C, et al.: Iodine biokinetics and 
radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with 
thyroid hormone withdrawal. J Clin Endocrinol Metab 2010,95(7):3283–3290. 10.1210/jc.2009-2528 
11.  Frigo A, Dardano A, Danese E, Davi MV, Moghetti P, Colato C, et al.: Chromosome translocation 
frequency after radioiodine thyroid remnant ablation: A comparison between recombinant hyman 
thyrotropin stimulation and prolonged levothyroxine withdrawal. J Clin Endocrinol Metab 
2009,94(9):3472–3476. 10.1210/jc.2008-2830 
12.  Menzel C, Kranert WT, Dobert N, Diehl M, Fietz T, Hamscho N, et al.: rhTSH stimulation before 
radioiodine therapy in thyroid cancer reduces the effective half-life of 131I. J Nucl Med 
2003,44(7):1065–1068. 
13.  Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, et al.: Ablation with low-dose radioiodine and 
thyropin alfa in thyroid cancer. N Engl J Med 2012,366(18):1674–1685. 10.1056/NEJMoa1109589 
14.  Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, et al.: Strategies of radioiodine 
ablation in patients with low-risk thyroid cancer. N Engl J Med 2012, 366: 1663–1673. 
10.1056/NEJMoa1108586 
15.  Bertenstein P, Calabuig EC, Maini CL, Mazzarotto R, Muros de Fuentes MA, Petrich T, et al.: High-risk 
patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using 
rhTSH or thyroid hormone withdrawal. Thyroid 2014,24(3):480–487. 10.1089/thy.2013.0157 
16.  Molinaro E, Giani C, Agate L, Biagini A, Brozzi F, Ceccarelli C, et al.: Patients with differentiated thyroid 
cancer who underwent radioiodine thyroid remnant ablation with low-activity 131I after either recombinant 
human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up. J 
Clin Endocrinol Metab 2013,98(7):2693–2700. 10.1210/jc.2012-4137 
17.  Luster M, Lassmann M, Haenscheid H, Michalowski U, Inerti C, Reiners C: Use of recombinant human 
thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. J Clin 
Endocrinol Metab 2000,85(10):3640–3645. 10.1210/jcem.85.10.6903 
18.  Jarząb B, Handkiewicz-Junak D, Roskosz J, Puch Z, Wygoda Z, Kukulska A, et al.: Recombinant human 
TSH-aided radioiodine treatment of advanced differentiated tyroid carcinoma: a single-centre study of 54 
patients. Eur J Nucl Med Mol Imaging 2003,30(8):1077–1086. 10.1007/s00259-003-1190-5 
19.  Tala H, Robbins R, Gagin JA, Larson SM, Tuttle RM: Five-year survival is similar in thyroid cancer 
patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone 
withdrawal or recombinant human TSH. J Clin Endocrinol Metab 2011,96(7):2105–2111. 
10.1210/jc.2011-0305 
20.  Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W, et al.: European consensus for the 
management of patients with differentiated thyroid carcinoma of the follicular epithelium. European Journal 
of Endocrinology 2007,154(6):787–803. 
21.  Vera P, Kuhn-Lansoy C, Edet-Sanson A, Hapdey S, Modzelewski R, Hitzel A, et al.: Does recombinant 
human thyrotropin-stimulated Positron Emission Tomography with [18F]Fluoro-2-Deoxy-D-Glucose 
improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum 
thyroglobulin? Thyroid 2010,20(1):15–23. 10.1089/thy.2008.0416 
